[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624915":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":49,"id":53,"slug":11,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"study group","EXPERIMENTAL",null,[13],"Diagnostic Test: dosage of blood biomarker miR1",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","dosage of blood biomarker miR1","Patients and controls will be asked to provide blood samples to evaluate their blood level of miR1 biomarker on a unique time participation.",[9],[21],{"name":22,"affiliation":5,"role":23},"Catherine Sarret, MD, PhD, Prof","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Lise Laclautre, PhD","CONTACT","+33473750750","promo_interne_drci@chu-clermontferrand.fr",[31],{"facility":32,"status":33,"city":34,"state":11,"zip":11,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"CHU de Clermont-Ferrand","RECRUITING","Clermont-Ferrand","France",{"type":37,"coordinates":38},"Point",[39,40],3.08682,45.77969,{"lat":40,"lon":39},[43,45],{"name":44,"role":27,"phone":11,"phoneExt":11,"email":29},"Lise Laclautre",{"name":46,"role":23,"phone":11,"phoneExt":11,"email":11},"Catherine Sarret",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[50],{"name":51,"class":52},"iGreD, Université Clermont Auvergne","UNKNOWN","100624915",false,"NCT07415837","Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies","Dystro-miR1","Inclusion Criteria:\n\n* Age: Participants must be older than 2 years of age\n* Consent: Participants (or their legal guardians) must provide free and informed consent,. For children, the consent is oral for those under 6 years old and written for those over 6,.\n* Social Security: Every participant must be affiliated with the French social security system.\n* Participants must have a diagnosed neuromuscular pathology : the eligible pathologies are Myotonic Dystrophy Type 1 (DM1 or Steinert's disease), Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (DMB), or congenital myopathies or are healthy participants.\n\nExclusion Criteria:\n\n* Refusal to participate expressed by the subject or their parental authority.\n* Engaging in intense and unusual physical effort within 10 days before the blood draw.\n* Current use of any treatment with systemic, muscular, or cardiac effects that could interfere with the study's biological results.\n* Subjects or their legal guardians who are under tutelage, curatorship, deprived of liberty, or under judicial protection.\n* Women who are pregnant or breastfeeding.\n* The presence of an additional pathology that, in the judgment of the clinician, could interfere with the biological findings",true,"ALL","2 Years",{"count":63,"type":64},104,"ESTIMATED","INTERVENTIONAL",[67],"NA","The study aims to find out if a specific blood molecule called miR-1, can be used as a biomarker to track the health of patients with certain muscle diseases.\n\nMicroRNAs (miRs) are small messengers that help control how cells grow and stay healthy. Some of these, like miR-1, are specifically found in muscles and the heart. Research shows that levels of miR-1 are often abnormal in people with muscle-wasting conditions, but more information are needed to understand how this relates to the severity of the disease.\n\nThe main goal is to compare the blood levels of miR-1 between four different groups at different ages and severities:\n\n1. Patients with Duchenne or Becker muscular dystrophy (DMD\u002FDMB).\n2. Patients with Myotonic Dystrophy Type 1 (Steinert's disease).\n3. Patients with congenital myopathies.\n4. Healthy volunteers (control group). The main objective is to assess if miR-1 levels can accurately show how a muscular disease is progressing.",[70,71,72,73],"Duchenne \u002F Becker Muscular Dystrophy","Dystrophia Myotonica 1","Congenital Myopathies","Healthy Participants",[75,76,77],"biomarkers","neuromuscular diseases","micro-RNAs","2026-02-24",{"date":80,"type":81},"2026-02-25","ACTUAL",{"date":83,"type":81},"2026-02-11",{"date":85,"type":64},"2029-03",{"name":5,"class":6},1]